The significance of plasma C-reactive protein in patients with elevated serum prostate-specific antigen levels

Urological Science

Volumn 21, Issue 2, 2010, Pages 88-92

  Chang, Chang Chi ^a,b,c   Lin, Alex T L ^b,c   Chen, Kuang Kuo ^b,c   Chung, Hsiao Jen ^b,c   Chang, Shyh Chyi ^b,c,d  

^a TAIPEI CITY HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d LOTUNG POH AI HOSPITAL   (Taiwan)

Author keywords

Plasma C reactive protein; Prostate cancer; Prostate size; Prostate specific antigen

Indexed keywords

C REACTIVE PROTEIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE MARKER; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PROSTATE CANCER; PROTEIN BLOOD LEVEL;

EID: 77955022009     PISSN: 18795226     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1879-5226(10)60018-8     Document Type: Article

References (29)

1. Glenski WJ, Malek RS, Myrtle JF, Oesterling JE Sustained, substantially increased concentration of prostate-specific antigen in the absence of prostatic malignant disease: an unusual scenario. Mayo Clin Proc 1992, 67:249-252.
2. Oesterling JE Prostate-specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991, 145:907-923.
3. Pansadoro V, Emiliozzi P, Defidio L, et al. Prostate-specific antigen and prostatitis in men under fifty. Eur Urol 1996, 30:24-27.
4. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate antigen levels. J Urol 1995, 154:407-413.
5. Bataille R, Klein B C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum 1992, 35:982-984.
6. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998, 128:127-137.
7. Cesur S, Sunguroglu K, Ahmed K, Tezeren D, Keseci NO, Aksaray S Serum adenosine deaminase levels in patients with brucellosis and in healthy subjects. Turk J Med Sci 2004, 34:315-318.
8. Terris MK, Stamy TA Determination of prostate volume by transrectal ultrasound. J Urol 1991, 145:984-987.
9. Greene FL, Page DL, Fleming ID, et al. Prostate. AJCC Cancer Staging Manual 2002, 309-316. Springer-Verlag, New York. 6th ed. F.L. Greene, D.L. Page, I.D. Fleming (Eds.).
10. Kreder KJ, Williams RD Urologic laboratory examination. Smith's General Urology 2004, 49-61. McGraw-Hill, New York. 16th ed. E.A. Tanagho, J.W. McAninch (Eds.).
11. Schatteman PHF, Hoekx L, Wyndaele JJ, Jeuris W, Van Marck E Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis. Eur Urol 2000, 37:404-412.
12. Game X, Vincendeau S, Palascak R, Milcent S, Fournier R, Houlgatte A Total and free serum prostate specific antigen levels during the first month of acute prostatitis. Eur Urol 2003, 43:702-705.
13. Brawer MK, Rennels MA, Nagle RB, Schifman R, Gaines JA Serum prostate specific antigen and prostate pathology in men having simple prostatectomy. Am J Clin Pathol 1989, 92:760-764.
14. Morote-Robles J, Ruibal-Morell A, Palou-Redorta J, et al. Clinical behavior of prostatic specific antigen and prostatic acid phosphatase: a comparative study. Eur Urol 1988, 14:360-366.
15. Dalton DL Elevated serum prostate specific antigen due to acute bacterial prostatitis. Urology 1989, 33:465-466.
16. Kohnen PW, Drach GW Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol 1979, 121:755-760.
17. Nickel JC, Downey J, Young I, Boag S Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999, 84:976-981.
18. Irani J, Levillain P, Goujon JM, Bon D, Dore B, Aubert J Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol 1997, 157:1301-1303.
19. Okada K, Kojima M, Naya Y, et al. Correlation of histological inflammation in needle biopsy specimens with serum prostate-specific antigen levels in men with negative biopsy for prostate cancer. Urology 2000, 55:892-898.
20. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999, 41:127-133.
21. Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate 2005, 62:27-33.
22. Palapattu GS, Sutcliffe S, Bastian PJ, et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2004, 26:1170-1181.
23. Platz EA, De Marzo AM Epidemiology of inflammation and prostate cancer. J Urol 2004, 171:S36-S40.
24. Mahmud S, Franco E, Aprikian A Prostate cancer and use of nonsteroid anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 2004, 90:93-99.
25. Lehrer S, Diamond EJ, Mamkine B, Droller MJ, Stone NN, Stock RG C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int 2005, 95:961-962.
26. Latif Z, McMillan DC, Wallace AM, et al. The relationship of circulating insulin-like growth factor 1, its binding protein-3, prostate-specific antigen and C-reactive protein with disease stage in prostate cancer. BJU Int 2002, 89:396-399.
27. Trautner K, Cooper EH, Haworth S, Ward AM An evaluation of serum protein profiles in the long-term surveillance of prostate cancer. Scand J Urol Nephrol 1980, 14:143-149.
28. McArdle PA, McMillan DC, Sattar N, Wallace AM, Underwood MA The relationship between interleukin-6 and C-reactive protein in patients with benign and malignant prostate disease. Br J Cancer 2004, 91:1755-1757.
29. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001, 58:1008-1015.